Wiegmans, Adrian P <br/><br/>
RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy.  [electronic resource] 

 -  Oncotarget  09 2016 
 - 60087-60100 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.11065  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Cell Survival--drug effects<br/>Humans<br/>Imidazoles--administration & dosage<br/>Mice, Inbred BALB C<br/>Mice, Nude<br/>Mitogen-Activated Protein Kinase 14--antagonists & inhibitors<br/>Poly (ADP-Ribose) Polymerase-1--antagonists & inhibitors<br/>Pyridines--administration & dosage<br/>Quinazolinones--administration & dosage<br/>Rad51 Recombinase--antagonists & inhibitors<br/>Signal Transduction<br/>Triple Negative Breast Neoplasms--drug therapy<br/>Xenograft Model Antitumor Assays--methods